The Europe Atopic Dermatitis Drugs Market would witness market growth of 9.0% CAGR during the forecast period (2022-2028).
Transepidermal water loss (TEWL) is far more common in atopic dermatitis sufferers than in healthy individuals, and xerotic portions of these patients' skin experience more TEWL than healthy skin does. Ceramide levels are noticeably lower in the epidermis' outermost layer. The lack of ceramide leads to the xerosis that is a hallmark of atopic dermatitis because ceramide stores water in the extracellular space of this horny layer.
The increased TEWL and decreased ceramide protection also allow for greater antigen penetration, and increasing infection rates, which can subsequently cause the release of pruritogenic, pro-inflammatory mediators by activating the cytokine cascade launched by the epidermis.
Patients with AD are more likely to develop other atopic conditions such as asthma and allergic rhinitis. According to clinical observations, patients can experience what has been dubbed the "atopic march," which is a progression from AD to the onset of asthma and allergic rhinitis.
The prevalence of allergic illnesses is a significant contributor to patient morbidity and healthcare utilization. Epidemiological research suggests that in many western nations, the prevalence of organ-specific allergy illnesses has increased in recent years. These disorders include allergic rhinitis and eczema. Geographic variations in the incidence of these illnesses in both children and adults6 are equally startling. Anaphylaxis and food allergies, among other systemic allergic disorders, appear to be on the rise over the past ten years.
The Germany market dominated the Europe Atopic Dermatitis Drugs Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1,382.3 million by 2028.The UK market is estimated to grow a CAGR of 8.1% during (2022 - 2028). Additionally, The France market would experience a CAGR of 9.8% during (2022 - 2028).
Based on Route of Administration, the market is segmented into Injectable, Oral and Topical. Based on Class, the market is segmented into Biologics, Calcineurin Inhibitors, Corticosteroids, PDE4 Inhibitors and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Atopic Dermatitis Drugs Market will Hit $22 Billion by 2028, at a CAGR of 9.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer Inc., Sanofi SA, AbbVie Inc., Galderma S.A., Eli Lilly and Company, Leo Pharma A/S, Regeneron Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Novartis AG, and Incyte Corporation.
Scope of the Study
Market Segments Covered in the Report:
By Route of Administration
By Class
- Biologics
- Calcineurin Inhibitors
- Corticosteroids
- PDE4 Inhibitors
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Pfizer Inc.
- Sanofi SA
- AbbVie Inc.
- Galderma S.A.
- Eli Lilly and Company
- Leo Pharma A/S
- Regeneron Pharmaceuticals Inc.
- Otsuka Pharmaceutical Co. Ltd.
- Novartis AG
- Incyte Corporation
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Atopic Dermatitis Drugs Market, by Route of Administration
1.4.2 Europe Atopic Dermatitis Drugs Market, by Class
1.4.3 Europe Atopic Dermatitis Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Acquisition and Mergers
3.2.2 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers : 2018, Sep – 2022, Oct) Leading Players
Chapter 4. Europe Atopic Dermatitis Drugs Market by Route of Administration
4.1 Europe Injectable Market by Country
4.2 Europe Oral Market by Country
4.3 Europe Topical Market by Country
Chapter 5. Europe Atopic Dermatitis Drugs Market by Class
5.1 Europe Biologics Market by Country
5.2 Europe Calcineurin Inhibitors Market by Country
5.3 Europe Corticosteroids Market by Country
5.4 Europe PDE4 Inhibitors Market by Country
5.5 Europe Others Market by Country
Chapter 6. Europe Atopic Dermatitis Drugs Market by Country
6.1 Germany Atopic Dermatitis Drugs Market
6.1.1 Germany Atopic Dermatitis Drugs Market by Route of Administration
6.1.2 Germany Atopic Dermatitis Drugs Market by Class
6.2 UK Atopic Dermatitis Drugs Market
6.2.1 UK Atopic Dermatitis Drugs Market by Route of Administration
6.2.2 UK Atopic Dermatitis Drugs Market by Class
6.3 France Atopic Dermatitis Drugs Market
6.3.1 France Atopic Dermatitis Drugs Market by Route of Administration
6.3.2 France Atopic Dermatitis Drugs Market by Class
6.4 Russia Atopic Dermatitis Drugs Market
6.4.1 Russia Atopic Dermatitis Drugs Market by Route of Administration
6.4.2 Russia Atopic Dermatitis Drugs Market by Class
6.5 Spain Atopic Dermatitis Drugs Market
6.5.1 Spain Atopic Dermatitis Drugs Market by Route of Administration
6.5.2 Spain Atopic Dermatitis Drugs Market by Class
6.6 Italy Atopic Dermatitis Drugs Market
6.6.1 Italy Atopic Dermatitis Drugs Market by Route of Administration
6.6.2 Italy Atopic Dermatitis Drugs Market by Class
6.7 Rest of Europe Atopic Dermatitis Drugs Market
6.7.1 Rest of Europe Atopic Dermatitis Drugs Market by Route of Administration
6.7.2 Rest of Europe Atopic Dermatitis Drugs Market by Class
Chapter 7. Company Profiles
7.1 Pfizer, Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Regional & Segmental Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Approvals and Trials:
7.1.5.2 Acquisition and Mergers:
7.2 Novartis AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.3 Sanofi S.A.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.3.5.2 Acquisition and Mergers:
7.4 LEO Pharma A/S
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Approvals and Trials:
7.4.5.2 Acquisition and Mergers:
7.5 Incyte Corporation
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Research & Development Expenses
7.5.4 Recent strategies and developments:
7.5.4.1 Approvals and Trials:
7.5.4.2 Acquisition and Mergers:
7.6 AbbVie, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Approvals and Trials:
7.6.5.2 Acquisition and Mergers:
7.7 Regeneron Pharmaceuticals, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Research & Development Expense
7.8 Eli Lilly And Company
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.9 Otsuka Pharmaceutical Co., Ltd.
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Approvals and Trials:
7.9.2.2 Acquisition and Mergers:
7.10. Galderma S.A.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Acquisition and Mergers:
TABLE 1 Europe Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 2 Europe Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 3 Acquisition and Mergers– Atopic Dermatitis Drugs Market
TABLE 4 Approvals and trials – Atopic Dermatitis Drugs Market
TABLE 5 Europe Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 6 Europe Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 7 Europe Injectable Market by Country, 2018 - 2021, USD Million
TABLE 8 Europe Injectable Market by Country, 2022 - 2028, USD Million
TABLE 9 Europe Oral Market by Country, 2018 - 2021, USD Million
TABLE 10 Europe Oral Market by Country, 2022 - 2028, USD Million
TABLE 11 Europe Topical Market by Country, 2018 - 2021, USD Million
TABLE 12 Europe Topical Market by Country, 2022 - 2028, USD Million
TABLE 13 Europe Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 14 Europe Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 15 Europe Biologics Market by Country, 2018 - 2021, USD Million
TABLE 16 Europe Biologics Market by Country, 2022 - 2028, USD Million
TABLE 17 Europe Calcineurin Inhibitors Market by Country, 2018 - 2021, USD Million
TABLE 18 Europe Calcineurin Inhibitors Market by Country, 2022 - 2028, USD Million
TABLE 19 Europe Corticosteroids Market by Country, 2018 - 2021, USD Million
TABLE 20 Europe Corticosteroids Market by Country, 2022 - 2028, USD Million
TABLE 21 Europe PDE4 Inhibitors Market by Country, 2018 - 2021, USD Million
TABLE 22 Europe PDE4 Inhibitors Market by Country, 2022 - 2028, USD Million
TABLE 23 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 24 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 25 Europe Atopic Dermatitis Drugs Market by Country, 2018 - 2021, USD Million
TABLE 26 Europe Atopic Dermatitis Drugs Market by Country, 2022 - 2028, USD Million
TABLE 27 Germany Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 28 Germany Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 29 Germany Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 30 Germany Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 31 Germany Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 32 Germany Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 33 UK Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 34 UK Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 35 UK Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 36 UK Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 37 UK Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 38 UK Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 39 France Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 40 France Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 41 France Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 42 France Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 43 France Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 44 France Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 45 Russia Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 46 Russia Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 47 Russia Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 48 Russia Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 49 Russia Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 50 Russia Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 51 Spain Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 52 Spain Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 53 Spain Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 54 Spain Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 55 Spain Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 56 Spain Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 57 Italy Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 58 Italy Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 59 Italy Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 60 Italy Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 61 Italy Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 62 Italy Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 63 Rest of Europe Atopic Dermatitis Drugs Market, 2018 - 2021, USD Million
TABLE 64 Rest of Europe Atopic Dermatitis Drugs Market, 2022 - 2028, USD Million
TABLE 65 Rest of Europe Atopic Dermatitis Drugs Market by Route of Administration, 2018 - 2021, USD Million
TABLE 66 Rest of Europe Atopic Dermatitis Drugs Market by Route of Administration, 2022 - 2028, USD Million
TABLE 67 Rest of Europe Atopic Dermatitis Drugs Market by Class, 2018 - 2021, USD Million
TABLE 68 Rest of Europe Atopic Dermatitis Drugs Market by Class, 2022 - 2028, USD Million
TABLE 69 Key Information – Pfizer, Inc.
TABLE 70 Key Information – Novartis AG
TABLE 71 Key Information – Sanofi S.A.
TABLE 72 key information – LEO Pharma A/S
TABLE 73 Key Information – INCYTE CORPORATION
TABLE 74 Key information – AbbVie, Inc.
TABLE 75 Key Information – Regeneron Pharmaceuticals, Inc.
TABLE 76 Key Information – Eli Lilly And Company
TABLE 77 key information – Otsuka Pharmaceutical Co., Ltd.
TABLE 78 Key Information – Galderma S.A.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
FIG 4 Key Strategic Move: (Acquisitions and Mergers: 2018, SeP – 2022, Oct) Leading Players
FIG 5 Recent strategies and developments: Pfizer, Inc.
FIG 6 Recent strategies and developments: sanofi s.a.
FIG 7 Recent strategies and developments: leo pharma a/s